



Altimune to Participate at Two Upcoming Investor Conferences

June 3, 2022

GAITHERSBURG, Md., June 03, 2022 (GLOBE NEWSWIRE) -- Altimune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate at the following investor conferences in June 2022:

- **Jefferies 2022 Global Healthcare Conference in New York, NY**

Friday, June 10, 2022

Fireside chat at 10:00 am Eastern Time

- **JMP Securities Life Sciences Conference in New York, NY**

Thursday, June 16, 2022

Fireside chat at 9:00 am Eastern Time

The sessions will be webcast and can be accessed by visiting the [Events](#) section of the Altimune website.

About Altimune

Altimune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.

Follow @Altimune, Inc. on [LinkedIn](#)

Follow @AltimuneInc on [Twitter](#)

Altimune Investor & Media Contact:

Richard Eisenstadt

Chief Financial Officer

Phone: 240-654-1450

reisenstadt@altimmune.com



Source: Altimune, Inc